Cancer is the leading cause of death worldwide. Although significant advances are being made to fight against the disease, it remains a key public health concern and tremendous burden of our society; whereas metastasis is the major cause of death from cancer. Recent studies suggest that a subset of tumour cells called Cancer Stem Cells (CSCs) that have the ability to self-renew through key transcription factor mediated cell cycle progression and differentiation into different cell lineages, is responsible for tumour progression, metastasis and resistance to therapy. As CSCs are considered as a root of cancer origin and recurrence as well as drivers of intratumoral heterogeneity modulated by tumor microenvironment, it is crucial to understand the molecular mechanism of cancer progression and metastasis through multi-omics approaches. In addition, there are a large number of potential biomarkers that have been identified and validated in clinical samples. Hence, there is an urgent need for quantification of those minimally invasive biomarkers with high sensitivity and selectivity. In this context, biosensors are very promising tools for early diagnosis. Keeping these considerations in mind, this special issue will emphasize two major aspects: Firstly, understanding the key transcription factor mediated cell cycle progression and metastasis mechanism using multi-omics approaches and ‘big’-sized complex datasets analysis using artificial intelligence that might open up new opportunities in drug discovery development. Secondly, biosensors-based approaches for early detection of solid cancer biomarkers. Overall, this multidisciplinary approach is expected to have a great impact in biomedical research.
The major goal of this special issue is:
• To focus on understanding key transcription factors mediated molecular mechanisms of solid cancer progression and metastasis based on integration of multi-omics approaches including Genomics, Transcriptomic, Proteomic and Metabolomic datasets obtained from patients.
• Novel findings on “lab to clinic” based biosensor approach for point-of-care applications on early detection of solid cancer biomarkers.
Scope of the Research Topic:
1. Determining the molecular mechanism of Transcription factor mediated cell cycle progression and metastasis in solid cancer cells. To address this, a wide variety of state-of-the-art technologies will be applied.
2. Analysis of multi layered omics datasets and large scale omics studies for understanding of cancer progression at molecular level. To address this, emerging artificial intelligence will be poised to improve the precision of diagnostic and therapeutic methods in medicine.
3. Study on Biosensor based Point-of-care applications for early detection of cancer biomarkers. To address this, we will be designing and developing advanced platforms for rapid diagnostics of various biomarkers of cancers.
All together, this framework may help to predict treatment strategy, therapeutic response, overall survival of the patients and also might open new opportunity in drug development
To achieve the above mentioned goals, we are interested in providing quality research articles, mini-reviews, full reviews, and communications in the above specified fields.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
Cancer is the leading cause of death worldwide. Although significant advances are being made to fight against the disease, it remains a key public health concern and tremendous burden of our society; whereas metastasis is the major cause of death from cancer. Recent studies suggest that a subset of tumour cells called Cancer Stem Cells (CSCs) that have the ability to self-renew through key transcription factor mediated cell cycle progression and differentiation into different cell lineages, is responsible for tumour progression, metastasis and resistance to therapy. As CSCs are considered as a root of cancer origin and recurrence as well as drivers of intratumoral heterogeneity modulated by tumor microenvironment, it is crucial to understand the molecular mechanism of cancer progression and metastasis through multi-omics approaches. In addition, there are a large number of potential biomarkers that have been identified and validated in clinical samples. Hence, there is an urgent need for quantification of those minimally invasive biomarkers with high sensitivity and selectivity. In this context, biosensors are very promising tools for early diagnosis. Keeping these considerations in mind, this special issue will emphasize two major aspects: Firstly, understanding the key transcription factor mediated cell cycle progression and metastasis mechanism using multi-omics approaches and ‘big’-sized complex datasets analysis using artificial intelligence that might open up new opportunities in drug discovery development. Secondly, biosensors-based approaches for early detection of solid cancer biomarkers. Overall, this multidisciplinary approach is expected to have a great impact in biomedical research.
The major goal of this special issue is:
• To focus on understanding key transcription factors mediated molecular mechanisms of solid cancer progression and metastasis based on integration of multi-omics approaches including Genomics, Transcriptomic, Proteomic and Metabolomic datasets obtained from patients.
• Novel findings on “lab to clinic” based biosensor approach for point-of-care applications on early detection of solid cancer biomarkers.
Scope of the Research Topic:
1. Determining the molecular mechanism of Transcription factor mediated cell cycle progression and metastasis in solid cancer cells. To address this, a wide variety of state-of-the-art technologies will be applied.
2. Analysis of multi layered omics datasets and large scale omics studies for understanding of cancer progression at molecular level. To address this, emerging artificial intelligence will be poised to improve the precision of diagnostic and therapeutic methods in medicine.
3. Study on Biosensor based Point-of-care applications for early detection of cancer biomarkers. To address this, we will be designing and developing advanced platforms for rapid diagnostics of various biomarkers of cancers.
All together, this framework may help to predict treatment strategy, therapeutic response, overall survival of the patients and also might open new opportunity in drug development
To achieve the above mentioned goals, we are interested in providing quality research articles, mini-reviews, full reviews, and communications in the above specified fields.
Important Note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) will not be accepted in any of the sections of Frontiers in Oncology.
